Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.78 USD
Change Today -0.0292 / -3.60%
Volume 123.2K
BGMD On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 04/20/15 All times are local (Market data is delayed by at least 15 minutes).

bg medicine inc (BGMD) Snapshot

Open
$0.81
Previous Close
$0.81
Day High
$0.81
Day Low
$0.78
52 Week High
05/1/14 - $1.50
52 Week Low
12/15/14 - $0.27
Market Cap
27.0M
Average Volume 10 Days
155.5K
EPS TTM
$-0.24
Shares Outstanding
34.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BG MEDICINE INC (BGMD)

bg medicine inc (BGMD) Related Businessweek News

No Related Businessweek News Found

bg medicine inc (BGMD) Details

BG Medicine, Inc., a commercial stage company, engages in developing and commercializing diagnostic products used to guide the patients suffering from heart failure and related disorders. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke. It has license, development, and commercialization agreements with Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. for the automated instrument versions of galectin-3 test; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.

7 Employees
Last Reported Date: 03/31/15
Founded in 2000

bg medicine inc (BGMD) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $258.5K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $275.0K
Compensation as of Fiscal Year 2013.

bg medicine inc (BGMD) Key Developments

BG Medicine, Inc. Announces Resignation of Brian S. Posner from the Board of Directors

Brian S. Posner notified BG Medicine, Inc. (the company) that he was resigning from the company's Board of Directors (the Board), effective as of April 15, 2015.

BG Medicine, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

BG Medicine, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total revenues of $554,000 against $1,149,000 a year ago. Loss from operations was $1,211,000 against $1,661,000 a year ago. Net loss was $1,319,000 against $1,935,000 a year ago. Basic and diluted loss per share was $0.04 against $0.06 a year ago. The decrease in total revenues reflected a $330,000 decrease in product revenues and a $265,000 decrease in service revenues from the prior year quarter. For the year, the company reported total revenues of $2,787,000 against $4,073,000 a year ago. Loss from operations was $7,362,000 against $14,374,000 a year ago. Net loss was $8,064,000 against $15,849,000 a year ago. Basic and diluted loss per share was $0.25 against $0.58 a year ago. Net cash used in operating activities was $8,167,000 against $15,288,000 a year ago.

BG Medicine, Inc. Auditor Raises 'Going Concern' Doubt

BG Medicine, Inc. filed its 10-K on Mar 31, 2015 for the period ending Dec 31, 2014. In this report its auditor, Deloitte & Touche LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BGMD:US $0.78 USD -0.0292

BGMD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alere Inc $50.05 USD +0.47
Bio-Reference Laboratories Inc $34.87 USD +0.29
BioMerieux €91.89 EUR -0.11
Laboratory Corp of America Holdings $125.35 USD +0.94
Quest Diagnostics Inc $76.15 USD +0.82
View Industry Companies
 

Industry Analysis

BGMD

Industry Average

Valuation BGMD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.0x
Price/Book 50.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BG MEDICINE INC, please visit www.bg-medicine.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.